



CI Insight Report - NASH -

[Sample Table of Contents]

September 2023

Social Survey Research Information Co., Ltd.

§ Report TOPICS

Diseases under investigation	NASH (nonalcoholic steatohepatitis)	
Survey Points/ Topics	Patient trends	<ul style="list-style-type: none"> ➤ Analysis and verification of the consultation status of patients with NAFLD/NASH ➤ Analysis and verification of the underlying (comorbid) disease status of NASH patients <p>⇒ In-depth analysis of the actual status of NASH patients!</p>
	Diagnostic trends	<ul style="list-style-type: none"> ➤ Analysis and verification of differential diagnosis status of NASH patients <p>⇒ What is the actual use of liver biopsy?</p> <p>⇒ In-depth analysis of the actual status of NASH diagnosis!</p>
	Existing drugs/ Existing treatment	<ul style="list-style-type: none"> ➤ Analysis and verification of prescription status and evaluation of existing drugs by stage <p>⇒ What are realistic prescription drugs for NASH treatment purposes?</p> <ul style="list-style-type: none"> ➤ Verification of realistic clinical treatment goals <p>⇒ In-depth verification of the reality and unmet needs for existing treatment!</p>
	New drugs	<ul style="list-style-type: none"> ➤ Verification and forecast of the potential and prescribing trends of a high-profile drug, semaglutide ➤ Analysis and verification of the potential of drugs developed in Japan and overseas <p>⇒ In-depth verification of the potential of new drugs!</p>

§ Report TOPICS

Diseases under investigation	NASH (non-alcoholic steatohepatitis)	
Survey Points/ Topics	Clinical development direction	<ul style="list-style-type: none">➤ Analysis and verification of past development failure factors➤ Verification of key points for successful development <p>⇒ In-depth forecast of the direction of future clinical development!</p> <p>(What triggers the approval?)</p>

■ Major Survey Subjects

Means of diagnosis			<ul style="list-style-type: none"> • Liver biopsy • MR/ultrasound (fibroscan) elastography • Fibrosis markers (hyaluronic acid, type IV collagen 7s, M2BPGi) 	
Remedy	Existing drugs		Antidiabetic drug	SGLT2 inhibitors, GLP-1 receptor agonists
			Dyslipidemia drug	Fibrates
			Antihypertensive drug	ARB
			Other	Vitamin E
	New drugs (developed drugs)	Domestic/ Overseas deployment	GLP-1 receptor agonist	Semaglutide
			GLP-1/ACC inhibitor/FXR activator	Semaglutide/GS0976/GS-9674
			GIP/GLP-1	LY3298176 Tirzepatide
			GLP-1/Glucagon receptor	BI 456906
			PPAR α modulator/SGLT2 inhibitor	K-877-ER/CSG452 pemafibrate/tofogliflozin
		Overseas deployment	THR- β agonist	Resmetirom
			FGF21	Efruxifermin/pegozafermin

§ Summary by Report Part

Survey type	Part I Data analysis	Part II Quantitative survey	Part III KOL hearing
Survey method	Data analysis (based on open source)	Web survey via the Internet	Depth interview
Physicians surveyed/ Number of physicians surveyed	-	NASH clinicians Total 201	NASH TOP KOL 3 [board members of related academic societies]
Departments surveyed <Facility type>	-	Hepatology, gastroenterology, diabetology, internal medicine <HP/GP>	Gastroenterology (hepatologists) <HP>
Survey contents	<Existing drugs> List of therapeutic agents, clinical trials, related papers <Developed drugs (domestic/overseas)> Profile, mechanism of action/characteristics, clinical trials, related literatures <Others> Trends in notable companies, information on related academic societies <Attachment> Abstracts (related papers)	<Medical treatment/patient trends> ● NAFLD/NASH patient trends <The following items are related to NASH> ● Patient trends by stage ● Concomitant underlying diseases <Diagnosis status> ● Differential diagnosis methods ● Implementation status of liver biopsy/future change trends <Drug therapy implementation status> ● Drug therapy implementation targets ● Prescription drugs (for the treatment of NASH) ● Treatment goals/current unmet needs ● Forecast of future prescribing trends	<Patient trends> ● NAFLD/NASH patient trends <The following items are related to NASH> ● Concomitant underlying diseases <Diagnosis status> ● Differential diagnosis methods* ● Implementation status of noninvasive testing methods/use evaluation* <Drug therapy implementation status> ● Prescription drugs (for the treatment of NASH) ● Unmet needs for existing treatment* <Prescribing trends of a new drug, semaglutide> ● Drug evaluation/forecast of prescribing trends*

§ Summary by Report Part

Survey type	Part I Data analysis	Part II Quantitative survey	Part III KOL hearing
Survey contents		<p><Prescribing trends of a new drug, semaglutide></p> <ul style="list-style-type: none"> ● Post-approval prescription intention/prescription targets <p><Domestic/overseas new drugs (developed drugs)></p> <ul style="list-style-type: none"> ● Awareness, prescription intention and expectation by drug and so forth 	<p><Domestic/overseas new drugs (developed drugs)></p> <ul style="list-style-type: none"> ● Drug-specific potential analysis <p><Direction of clinical development></p> <ul style="list-style-type: none"> ● Future direction of clinical development* and so forth <p><u>*The verification/forecast of actual situations/future trends in whole Japan is included.</u></p>
Survey period	July - August 2023		
Style/Pages	Part I - PPT (or EXCEL), Part II & III - PPT / A4 total 300 pages (main report only, not including attachments)		
Report price	<p>Full set of report <3 parts> 1,900,000 yen (tax not included) *Parts can be sold separately</p> <p>*Option Row data 500,000 yen (tax not included)</p> <p>Row data + target matching 600,000 yen (tax not included)</p>		

<Part I Data Analysis Table of Contents>

Survey summary	3
■ Disease overview	4
I. Existing products	7
I-1. List of therapeutic agents	8
I-2. Clinical trials (UMIN)	9
I-3. Clinical trials (jRCT)	12
I-4. Clinical trials (UMIN&jRCT)	13
II. Developed products	14
II -1. Profile	15
II -2. Mechanism of action/characteristics	19
II -3. Clinical trials (jRCT)	26
III. Related company trends	30

IV. Information on academic societies	34
IV-1. The Japan Society of Hepatology	35
IV-2. The Japanese Society of Gastroenterology	37
IV-3. The Japan Society of Ultrasonics in Medicine	38
IV-4. Japan Digestive Disease Week	40
V. Related literatures	41
V-1-1. Existing products (by product)	42
V-1-2. Existing products (multiple)	45
V-2-1. Developed products (by product)	47
V-2-2. Developed products (multiple)	53
V-3. Existing products + developed products	54

<Part II Quantitative Survey Summary Table of Contents>

Survey summary	3
Respondent profile	4
§.Executive summary	5
§.Summary	15
1) Status of treatment for NAFLD	16
2) Status of treatment and diagnosis for NASH	17
3) Patient status by stage	21
4) Implementation status of drug therapy for NASH	40
5) Awareness and prescribing trends of semaglutide	69
6) Awareness of developed drugs, intention to prescribe, and expectation (domestic/overseas)	79
7) Future trends in liver biopsy implementation	83

<Part II Quantitative Survey Results Table of Contents>

Survey summary	3	4-3. Prescription status and purpose of prescribing therapeutic drugs	46
Respondent profile	4	4-4. Prescription status by drug	61
§ Survey results	5	4-5. Treatment satisfaction by drug	74
1) Status of treatment for NAFLD	6	4-6. Future prescription trends by drug	81
1-1. Number of patients treated and new patients (in the last 3 months)	7	4-7. Unmet needs for existing treatment	83
1-2. Consultation status (background of consultation)	8	5) Awareness and prescription trends of semaglutide	84
2) Status of treatment and diagnosis for NASH	9	5-1. Awareness status	85
2-1. Definitive diagnosis method	10	5-2. Post-approval prescribing intention (described separately based on liver biopsy implementation status)	86
2-2. Number of patients treated	12	5-3. Prescription targets (described separately based on liver biopsy implementation status)	88
2-3. Liver biopsy implementation status	13	5-4. Points to expect	94
3) Patient status by stage	14	6) Awareness of developed drugs, intention to prescribe, and expectations (domestic/overseas)	96
3-1. Stage classification implementation status	15	6-1. Awareness by drug	97
3-2. Stage classification method	16	6-2. Intention to prescribe by drug	100
3-3. Percentage of patients by stage	18	7) Future trends in liver biopsy implementation	104
3-4. Medical record entries by stage	19	7-1. Future increase rate of liver biopsy (subjects: physicians who perform liver biopsies)	105
3-5. Treatment status (diet, exercise, and drug therapy) by stage	20	7-2. Future plans for liver biopsies (subjects: physicians who do not perform liver biopsies)	106
3-6. Underlying disease status by stage	21		
4) NASH drug therapy implementation status	43		
4-1. Treatment goals	44		
4-2. Target stage of drug therapy			

<Part III KOL Hearings Table of Contents>

Survey summary	3
Summary	6
1. Patient trends	17
2. Diagnosis status	20
3. Drug therapy implementation status	23
4. Unmet needs for existing treatment	27
5. A new drug, semaglutide Evaluation and forecast of prescribing trends	30
6. Evaluation and impression of new drugs (developed drugs)	35
7. Direction of clinical development	39